Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Further Publications Immunology

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

J Rheumatol

Koppikar S, Kuriya B, Udell JA, Yu B, Chu A, Lee DS, Widdifield J, Eder L

doi: 10.3899/jrheum.2024-0866

Rheumatoid Arthritis

Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients

Semin Arthritis Rheum

Pappas DA, Reed G, Kane K, Curtis JR, Charles-Schoeman C, Giles JT, Kremer JM

doi: 10.1016/j.semarthrit.2024.152504

Rheumatoid Arthritis

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Arthritis Res Ther

Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, Strangfeld A, Meissner Y

doi: 10.1186/s13075-024-03449-9

Rheumatoid Arthritis

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Rheumatology (Oxford)

Choquette D, Haraoui B, Movahedi M, Bessette L, Sauvageau LC, Ferdinand I, Joly-Chevrier M, Masetto A, Massicotte F, Nadon V, Pelletier JP, Raynauld JP, Sauvageau D, Villeneuve É, Coupal L

doi: 10.1093/rheumatology/keae283

Rheumatoid Arthritis

Ultrasound of the forefeet besides the hands in patients at risk for rheumatoid arthritis: is it worth the effort? A longitudinal cohort study

Rheumatology (Oxford)

Boeren AMP, Oei EHG, Willemze A, de Jong PHP, van der Helm-van Mil AHM, van Mulligen E

doi: 10.1093/rheumatology/keae339

Rheumatoid Arthritis

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Ann Rheum Dis

van Mulligen E, Bour SS, Goossens LMA, de Jong PHP, Rutten-van Mölken M, van der Helm-van Mil A

doi: 10.1136/ard-2024-226286

Juvenile Idiopathic Arthritis

Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis

Arthritis Rheumatol

Tordoff M, Smith SL, Lawson-Tovey S, UK JIA Biologics Register, CAPS, CHARMS, CLUSTER, JIAGC, Dick AD, Beresford MW, Ramanan AV, Hyrich KL, Morris AP, Eyre S, Wedderburn LR, Bowes J, CLUSTER consortium

doi: 10.1002/art.42955

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Related content

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study

Effect of biologic agents and inflammation on lipid levels and cardiovascular risk in rheumatoid arthritis patients

Impact of systemic inflammation and disease activity on the incidence of interstitial lung disease in patients with rheumatoid arthritis - a nested case-control study within the German biologics register RABBIT

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Ultrasound of the forefeet besides the hands in patients at risk for rheumatoid arthritis: is it worth the effort? A longitudinal cohort study

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo-controlled TREAT EARLIER trial

Integration of genetic and clinical risk factors improves the risk classification of uveitis in patients with juvenile idiopathic arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort